Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

In the first three phases of Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) multicenter trials, 708 patients received intravenous recombinant tissue-type plasminogen activator (rt-PA) and underwent detailed assessment of clinical, angiographic and ventriculographic outcomes. The cumulative experience and data base afford the opportunity to address several important questions regarding aggressive therapy of myocardial infarction. These include predictive factors of in-hospital mortality, improvement of left ventricular function and the occurrence of recurrent ischemia. Consideration of practical issues, such as thrombolytic therapy for patients with cardiopulmonary resuscitation or previous stroke, use of coronary artery bypass surgery and the effect of operator experience on angioplasty success rate, has also been made possible. The major accomplishments as well as the deficiencies of the current approach to patient management after thrombolysis are reviewed, and the new TAMI trials currently underway are discussed.

Full Text

Duke Authors

Cited Authors

  • Topol, EJ; Califf, RM; George, BS; Kereiakes, DJ; Lee, KL

Published Date

  • December 1988

Published In

Volume / Issue

  • 12 / 6 Suppl A

Start / End Page

  • 24A - 31A

PubMed ID

  • 2973486

International Standard Serial Number (ISSN)

  • 0735-1097

Digital Object Identifier (DOI)

  • 10.1016/0735-1097(88)92638-1


  • eng

Conference Location

  • United States